Equillum

Equillum is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory disorders. The company's lead program, itolizumab, is a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, currently in Phase 3 clinical development for acute graft-versus-host disease (aGVHD). Equillum is also advancing a pipeline of multi-cytokine inhibitors, including EQ101 and EQ102, which target key signaling pathways involved in various dermatological and gastrointestinal conditions. By leveraging its expertise in immunology and its proprietary multi-cytokine platform, Equillum aims to provide transformative treatments for patients with high unmet medical needs.